Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
Decheng Capital Global Life Sciences Fund IV, L.P. - 31 Mar 2026 SCHEDULE 13G/A Report for Upstream Bio, Inc. Common Stock, par value $0.001 per share (UPB)
- Filing manager
- Decheng Capital Global Life Sciences Fund IV, L.P.
- Reporting owner
- Decheng Capital Global Life Sciences Fund IV, L.P.
- Beneficially owned shares
- 2,724,868 shares
- Large-stake signal
-
Ownership
5%Beneficial ownership of this reported class.
Shares
2,724,868 sharesShares beneficially owned as disclosed.
Event date
31 Mar 2026Date tied to the ownership event or amendment.
Accepted by SEC
15 May 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 5%
- Symbol
- UPB
- Shares outstanding
- 54,497,360 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 15 May 2026, 16:15:06 UTC
- Event date
- 31 Mar 2026
- Prior SEC filing
- 14 Feb 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
Decheng Capital Global Life Sciences Fund IV, L.P. disclosed 5% ownership in Upstream Bio, Inc. Common Stock, par value $0.001 per share (UPB) on 31 Mar 2026.
Key facts
- Decheng Capital Global Life Sciences Fund IV, L.P. filed SCHEDULE 13G/A for Upstream Bio, Inc. Common Stock, par value $0.001 per share (UPB).
- Disclosed ownership: 5%.
- Date of event: 31 Mar 2026.
Change
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 15 May 2026, 16:15.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (5)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. | 5% | 2,724,868 | 0 | 2,724,868 | /s/ Xiangmin Cui | By Decheng Capital Management IV (Cayman), LLC, its General Partner, By Xiangmin Cui, Manager | |
| Decheng Capital Management IV (Cayman), LLC | 5% | 2,724,868 | 0 | 2,724,868 | /s/ Xiangmin Cui | By Xiangmin Cui, Manager | |
| Decheng Capital Global Healthcare Fund (Master), LP | 0% | 0 | 0 | 0 | /s/ Xiangmin Cui | By Decheng Capital Global Healthcare GP, LLC, its General Partner, By Decheng Capital LLC, its Manager, By Xiangmin Cui, Manager | |
| Decheng Capital Global Healthcare GP, LLC | 0% | 0 | 0 | 0 | /s/ Xiangmin Cui | By Decheng Capital LLC, its Manager, By Xiangmin Cui, Manager | |
| Xiangmin Cui | 5% | 2,724,868 | 0 | 2,724,868 | /s/ Xiangmin Cui | Xiangmin Cui |
CIK / CUSIP context first